Kang Dong Woo, Choi Kang-Yell, Min Do Sik
Department of Molecular Biology, College of Natural Science, Pusan National University, Busan 609-735.
Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul 120-749, and; Translational Research Center for Protein Function Control, Yonsei University, Seoul 120-749, Korea.
J Biol Chem. 2014 Aug 15;289(33):22575-22582. doi: 10.1074/jbc.R114.569822. Epub 2014 Jul 2.
Phospholipase D (PLD) regulates downstream effectors by generating phosphatidic acid. Growing links of dysregulation of PLD to human disease have spurred interest in therapeutics that target its function. Aberrant PLD expression has been identified in multiple facets of complex pathological states, including cancer and inflammatory diseases. Thus, it is important to understand how the signaling network of PLD expression is regulated and contributes to progression of these diseases. Interestingly, small molecule PLD inhibitors can suppress PLD expression as well as enzymatic activity of PLD and have been shown to be effective in pathological mice models, suggesting the potential for use of PLD inhibitors as therapeutics against cancer and inflammation. Here, we summarize recent scientific developments regarding the regulation of PLD expression and its role in cancer and inflammatory processes.
磷脂酶D（PLD）通过生成磷脂酸来调节下游效应分子。PLD失调与人类疾病之间日益增多的联系激发了针对其功能的治疗方法的研究兴趣。在包括癌症和炎症性疾病在内的复杂病理状态的多个方面都已发现PLD表达异常。因此，了解PLD表达的信号网络如何被调节以及如何促进这些疾病的进展非常重要。有趣的是，小分子PLD抑制剂可以抑制PLD的表达及其酶活性，并且已在病理小鼠模型中显示出有效性，这表明PLD抑制剂有作为抗癌和抗炎治疗药物的潜力。在这里，我们总结了关于PLD表达调节及其在癌症和炎症过程中的作用的最新科学进展。
